Literature DB >> 15895708

Natural history of the cerebrovascular complications of Fabry disease.

A Mehta1, L Ginsberg.   

Abstract

UNLABELLED: Fabry disease is a rare, X-linked lysosomal storage disease caused by an inborn deficiency of alpha-galactosidase A, which results in progressive accumulation of globotriaosylceramide in a range of cells and tissues. Neurological symptoms of Fabry disease, including peripheral neuropathy and cerebrovascular events, are among the most significant clinical aspects. In this paper we present the natural history and mechanisms involved in the cerebrovascular complications of Fabry disease using data reported in FOS-- the Fabry Outcome Survey--and other registries and clinical studies. We discuss ways in which these manifestations can be modified by intervention, including both general measures for cerebrovascular disease and enzyme replacement therapy.
CONCLUSION: Data from FOS have provided important insights into the natural history of the cerebrovascular complications of Fabry disease. Furthermore, the database has demonstrated that significant renal or cardiac disease often co-exists with cerebrovascular disease, and may predispose patients with Fabry disease to neurological disability and stroke.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15895708     DOI: 10.1111/j.1651-2227.2005.tb02106.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  18 in total

Review 1.  Stroke Risk Factors, Genetics, and Prevention.

Authors:  Amelia K Boehme; Charles Esenwa; Mitchell S V Elkind
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

2.  Homocysteine and erythrocyte sedimentation rate correlate with cerebrovascular disease in fabry disease.

Authors:  R Cheung; D O Sillence; M C Tchan
Journal:  JIMD Rep       Date:  2012-02-01

3.  Auditing the frequency and the clinical and economic impact of testing for Fabry disease in patients under the age of 70 with a stroke admitted to Saint Vincent's University Hospital over a 6-month period.

Authors:  J Lambe; I Noone; R Lonergan; N Tubridy
Journal:  Ir J Med Sci       Date:  2017-05-03       Impact factor: 1.568

4.  Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.

Authors:  Akemi Tanaka; Taisuke Takeda; Takao Hoshina; Kazuyoshi Fukai; Tsunekazu Yamano
Journal:  J Inherit Metab Dis       Date:  2010-06-22       Impact factor: 4.982

Review 5.  Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry.

Authors:  Michael Beck; Uma Ramaswami; Elizabeth Hernberg-Ståhl; Derralynn A Hughes; Christoph Kampmann; Atul B Mehta; Kathleen Nicholls; Dau-Ming Niu; Guillem Pintos-Morell; Ricardo Reisin; Michael L West; Jörn Schenk; Christina Anagnostopoulou; Jaco Botha; Roberto Giugliani
Journal:  Orphanet J Rare Dis       Date:  2022-06-20       Impact factor: 4.303

Review 6.  2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.

Authors:  Chung-Lieh Hung; Yen-Wen Wu; Chih-Chan Lin; Chih-Hung Lai; Jimmy Jyh-Ming Juang; Ting-Hsing Chao; Ling Kuo; Kuo-Tzu Sung; Chao-Yung Wang; Chun-Li Wang; Chun-Yuan Chu; Wen-Chung Yu; Charles Jia-Yin Hou
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

Review 7.  Cognitive dysfunction and depression in Fabry disease: a systematic review.

Authors:  Fay E Bolsover; Elaine Murphy; Lisa Cipolotti; David J Werring; Robin H Lachmann
Journal:  J Inherit Metab Dis       Date:  2013-08-16       Impact factor: 4.982

Review 8.  Update on role of agalsidase alfa in management of Fabry disease.

Authors:  Uma Ramaswami
Journal:  Drug Des Devel Ther       Date:  2011-03-14       Impact factor: 4.162

9.  Fabry disease and early stroke.

Authors:  U Feldt-Rasmussen
Journal:  Stroke Res Treat       Date:  2011-06-23

10.  Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.

Authors:  L J Anderson; K M Wyatt; W Henley; V Nikolaou; S Waldek; D A Hughes; G M Pastores; S Logan
Journal:  J Inherit Metab Dis       Date:  2014-05-15       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.